Dammann R - Search Results

1

CpG island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.

Schagdarsurengin U, Gimm O, Dralle H, Hoang-Vu C, Dammann R. Schagdarsurengin U, et al. Among authors: dammann r. Thyroid. 2006 Jul;16(7):633-42. doi: 10.1089/thy.2006.16.633. Thyroid. 2006. PMID: 16889486

2

Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.

Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R. Schagdarsurengin U, et al. Among authors: dammann r. Cancer Res. 2002 Jul 1;62(13):3698-701. Cancer Res. 2002. PMID: 12097277

3

Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma.

Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, Boehm BO, Pfeifer GP, Hoang-Vu C. Dammann R, et al. Oncogene. 2003 Jun 12;22(24):3806-12. doi: 10.1038/sj.onc.1206582. Oncogene. 2003. PMID: 12802288

4

CpG island methylation and expression of tumour-associated genes in lung carcinoma.

Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst UE, Hofmann HS, Silber RE, Burdach S, Hansen G. Dammann R, et al. Eur J Cancer. 2005 May;41(8):1223-36. doi: 10.1016/j.ejca.2005.02.020. Eur J Cancer. 2005. PMID: 15911247

5

Frequent promoter methylation of tumor-related genes in sporadic and men2-associated pheochromocytomas.

Dammann R, Schagdarsurengin U, Seidel C, Trümpler C, Hoang-Vu C, Gimm O, Dralle H, Pfeifer GP, Brauckhoff M. Dammann R, et al. Exp Clin Endocrinol Diabetes. 2005 Jan;113(1):1-7. doi: 10.1055/s-2004-830522. Exp Clin Endocrinol Diabetes. 2005. PMID: 15662588

6

Frequent promoter hypermethylation of tumor-related genes in head and neck squamous cell carcinoma.

Steinmann K, Sandner A, Schagdarsurengin U, Dammann RH. Steinmann K, et al. Oncol Rep. 2009 Dec;22(6):1519-26. doi: 10.3892/or_00000596. Oncol Rep. 2009. PMID: 19885608

7

Frequent epigenetic inactivation of RASSF10 in thyroid cancer.

Schagdarsurengin U, Richter AM, Wöhler C, Dammann RH. Schagdarsurengin U, et al. Epigenetics. 2009 Nov 16;4(8):571-6. doi: 10.4161/epi.4.8.10056. Epub 2009 Nov 14. Epigenetics. 2009. PMID: 19934646 Free article.

8

Frequent epigenetic inactivation of the RASSF1A gene in hepatocellular carcinoma.

Schagdarsurengin U, Wilkens L, Steinemann D, Flemming P, Kreipe HH, Pfeifer GP, Schlegelberger B, Dammann R. Schagdarsurengin U, et al. Among authors: dammann r. Oncogene. 2003 Mar 27;22(12):1866-71. doi: 10.1038/sj.onc.1206338. Oncogene. 2003. PMID: 12660822

9

Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter.

Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R. Strunnikova M, et al. Among authors: dammann r. Mol Cell Biol. 2005 May;25(10):3923-33. doi: 10.1128/MCB.25.10.3923-3933.2005. Mol Cell Biol. 2005. PMID: 15870267 Free PMC article.

10

A polymorphism at codon 133 of the tumor suppressor RASSF1A is associated with tumorous alteration of the breast.

Schagdarsurengin U, Seidel C, Ulbrich EJ, Kölbl H, Dittmer J, Dammann R. Schagdarsurengin U, et al. Among authors: dammann r. Int J Oncol. 2005 Jul;27(1):185-91. Int J Oncol. 2005. PMID: 15942659

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

96 results

Search Page

Filters